Friedberg JW - Search Results

1

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM. Rodgers TD, et al. Among authors: friedberg jw. Leuk Lymphoma. 2021 Mar;62(3):598-605. doi: 10.1080/10428194.2020.1837796. Epub 2020 Oct 25. Leuk Lymphoma. 2021. PMID: 33100068

2

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.

Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA. Friedberg JW, et al. Leuk Res. 2004 Feb;28(2):139-47. doi: 10.1016/s0145-2126(03)00213-3. Leuk Res. 2004. PMID: 14654078 Clinical Trial.

3

Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.

Friedberg JW, Fisher RI. Friedberg JW, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26. doi: 10.1586/14737140.4.1.18. Expert Rev Anticancer Ther. 2004. PMID: 14748653 Review.

4

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. Friedberg JW, et al. Leuk Lymphoma. 2004 Jan;45(1):85-92. doi: 10.1080/1042819031000149430. Leuk Lymphoma. 2004. PMID: 15061202 Clinical Trial.

5

Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.

Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS. Brown JR, et al. Among authors: friedberg jw. Leuk Lymphoma. 2004 Feb;45(2):315-20. doi: 10.1080/10428190310001593157. Leuk Lymphoma. 2004. PMID: 15101717

6

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Friedberg JW, et al. Blood. 2005 Jan 15;105(2):489-95. doi: 10.1182/blood-2004-06-2156. Epub 2004 Sep 9. Blood. 2005. PMID: 15358617 Free article. Clinical Trial.

7

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Lyman GH, et al. J Clin Oncol. 2004 Nov 1;22(21):4302-11. doi: 10.1200/JCO.2004.03.213. Epub 2004 Sep 20. J Clin Oncol. 2004. PMID: 15381684

8

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.

Friedberg JW, Freedman AS. Friedberg JW, et al. Curr Treat Options Oncol. 2006 Jul;7(4):276-84. doi: 10.1007/s11864-006-0037-2. Curr Treat Options Oncol. 2006. PMID: 16916488 Review.

9

Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.

Schaefer-Cutillo J, Friedberg JW, Fisher RI. Schaefer-Cutillo J, et al. Among authors: friedberg jw. Oncology (Williston Park). 2007 Feb;21(2):203-12; discussion 214, 217, 221. Oncology (Williston Park). 2007. PMID: 17396483 Free article. Review.

10

The role of bortezomib in the treatment of lymphoma.

Barr P, Fisher R, Friedberg J. Barr P, et al. Cancer Invest. 2007 Dec;25(8):766-75. doi: 10.1080/07357900701579570. Cancer Invest. 2007. PMID: 18058474 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters